DNA and RNA vaccines represent groundbreaking advancements in vaccination technology. Unlike traditional vaccines that use weakened or inactivated viruses, DNA and RNA vaccines work by introducing genetic material (DNA or RNA) from the pathogen into the body. Once inside, the body's cells use this genetic material to produce a harmless part of the virus, triggering an immune response. These vaccines are highly adaptable, allowing for rapid development to combat emerging diseases like COVID-19. DNA vaccines deliver a small, circular DNA strand, while RNA vaccines use messenger RNA to instruct cells to create viral proteins. Both types are safe, efficient, and offer promising avenues for combating infectious diseases while potentially revolutionizing future vaccine development.
Khursheed Nadeem Anwer
IMUNON, United States
Ping Xie
Rutgers University, United States
Regina Au
BioMarketing Insight, United States
Madhu Khanna
University of Delhi, India
Ahmed Abdulazeez
BHRUT Trust, United KingdomSubmit your abstract Today
Title : The importance of post-marketing surveillance and real-world data for a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Nanoscopic SubATVax™ adjuvanted vaccines against influenza A types H3N2, H1N1 and influenza type B for subcutaneous administration
David Craig Wright, D4 Labs, LLC, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : A promising novel approach to DNA vaccines
Khursheed Nadeem Anwer, IMUNON, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Advances in vaccines: Revolutionizing disease prevention
Delia Teresa Sponza, Dokuz Eylul University, Turkey
Title : Overcoming biophysical characterization challenges of small antigens in dilute vaccine formulations
Eric Kemp, Merck & Co., United States
Title : Commensal bacteria drive B-cell lymphomagenesis in the setting of innate immunodeficiency
Ping Xie, Rutgers University, United States
Title : A combined LC-MS and immunoassay approach to characterize preservative-induced destabilization of human papillomavirus virus-like particles adsorbed to an aluminum-salt adjuvant
Ria T Caringal, University of Kansas, United States